Journal
DRUG DISCOVERY TODAY
Volume 21, Issue 5, Pages 850-855Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2016.04.004
Keywords
-
Categories
Funding
- Bristol-Myers Squibb
Ask authors/readers for more resources
Antibody-drug conjugates (ADCs) are emerging modalities in the pharmaceutical industry. The unique target-specific binding of antibody allows targeted delivery of cytotoxic small molecules to cancer cells, and thus expands the therapeutic window. However, in-depth characterization of ADCs is complex because it involves the characterization of antibody, conjugated molecules and antibody conjugates as a whole. In this review, we describe the practical use of mass spectrometry for ADC characterization including qualitative and quantitative analysis. Technical advances, limitations and future trends will also be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available